These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 30582752)
21. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668 [TBL] [Abstract][Full Text] [Related]
22. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR; Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175 [TBL] [Abstract][Full Text] [Related]
23. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830 [TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis. Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294 [TBL] [Abstract][Full Text] [Related]
25. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254 [TBL] [Abstract][Full Text] [Related]
26. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644 [TBL] [Abstract][Full Text] [Related]
27. The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer. Patel SJ; Trivedi GL; Darie CC; Clarkson BD J Cell Mol Med; 2017 Mar; 21(3):456-466. PubMed ID: 27680505 [TBL] [Abstract][Full Text] [Related]
28. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041 [TBL] [Abstract][Full Text] [Related]
29. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R Oncologist; 2021 Jan; 26(1):e78-e89. PubMed ID: 32885893 [TBL] [Abstract][Full Text] [Related]
30. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004 [TBL] [Abstract][Full Text] [Related]
31. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential. Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718 [TBL] [Abstract][Full Text] [Related]
32. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217 [TBL] [Abstract][Full Text] [Related]
33. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724 [TBL] [Abstract][Full Text] [Related]
34. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
35. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Ekstrand AI; Jönsson M; Lindblom A; Borg A; Nilbert M Fam Cancer; 2010 Jun; 9(2):125-9. PubMed ID: 19731079 [TBL] [Abstract][Full Text] [Related]
36. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731 [TBL] [Abstract][Full Text] [Related]
37. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084 [TBL] [Abstract][Full Text] [Related]
38. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related]
39. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298 [TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing. Er TK; Wang YY; Chen CC; Herreros-Villanueva M; Liu TC; Yuan SS Oral Dis; 2015 Oct; 21(7):872-8. PubMed ID: 26173098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]